Journal Scans
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
Pemetrexed-Carboplatin Is Inferior to Etoposide-Carboplatin in Advanced SCLC
MA Socinski, EF Smit, P Lorigan, K Konduri, M Reck, A Szczesna, J Blakely, P Serwatowski, NA Karaseva, T Ciuleanu, J Jassem, M Dediu, S Hong, C Visseren-Grul, A-R Hanauske, CK Obasaju, SC Guba, N Thatcher
20090731
2009 Aug 31
J Clin Oncol
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer
J Clin Oncol. 2009 Aug 31; Epub ahead of print, MA Socinski, EF Smit, P Lorigan, K Konduri, M Reck, A Szczesna, J Blakely, P Serwatowski, NA Karaseva, T Ciuleanu, J Jassem, M Dediu, S Hong, C Visseren-Grul, A-R Hanauske, CK Obasaju, SC Guba, N Thatcher
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Approximately 60% to 70% of patients with small-cell lung cancer (SCLC) have extensive-stage (ES) disease at diagnosis. For these patients, standard first-line therapy includes chemotherapy with etoposide plus a platinum derivative. Although response to chemotherapy is generally good (up to 80%), responses are short lived, at approximately 4 months, and median overall survival (OS) is only 9 to 11 months. Pemetrexed has been proposed as an agent that might yield better outcomes than current standard...
